

References

- Abuhelwa, Z., Alloghbi, A., & Nagasaka, M. (2022). A comprehensive review on antibody-drug conjugates (ADCs) in the treatment landscape of non-small cell lung cancer (NSCLC). *Cancer Treatment Reviews, 106*, 102393. <https://doi.org/10.1016/j.ctrv.2022.102393>
- American Cancer Society. (2023). *Survival Rates for Pancreatic Cancer*. <https://www.cancer.org/cancer/types/pancreatic-cancer/detection-diagnosis-staging/survival-rates.html>
- Birrer, M. J., Moore, K. N., Betella, I., & Bates, R. C. (2019). Antibody-drug conjugate-based therapeutics: state of the science. *JNCI: Journal of the National Cancer Institute, 111*(6), 538-549. <https://doi.org/10.1093/jnci/djz035>
- Burgos, M., Cavero-Redondo, I., Álvarez-Bueno, C., Galán-Moya, E. M., Pandiella, A., Amir, E., & Ocaña, A. (2022). Prognostic value of the immune target CEACAM6 in cancer: a meta-analysis. *Therapeutic Advances in Medical Oncology, 14*, 17588359211072621. <https://doi.org/10.1177/17588359211072621>
- Cheng, T. M., Murad, Y. M., Chang, C. C., Yang, M. C., Baral, T. N., Cowan, A., Tseng, S. H., Wong, A., Mackenzie, R., Shieh, D. B., & Zhang, J. B. (2014). Single domain antibody against carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6) inhibits proliferation, migration, invasion and angiogenesis of pancreatic cancer cells. *European Journal of Cancer, 50*(4), 713-721. <https://doi.org/10.1016/j.ejca.2012.07.019>
- Conilh, L., Sadilkova, L., Viricel, W., & Dumontet, C. (2023). Payload diversification: a key step in the development of antibody–drug conjugates. *Journal of Hematology & Oncology, 16*(1), 3. <https://doi.org/10.1186/s13045-022-01397-y>
- Fu, Z., Gao, C., Wu, T., Wang, L., Li, S., Zhang, Y., & Shi, C. (2023). Peripheral neuropathy associated with monomethyl auristatin E-based antibody-drug conjugates. *iScience, 26*(10), 107778. <https://doi.org/10.1016/j.isci.2023.107778>

- Ghasemi, M., Turnbull, T., Sebastian, S., & Kempson, I. (2021). The MTT assay: utility, limitations, pitfalls, and interpretation in bulk and single-cell analysis. *International journal of molecular sciences*, 22(23), 12827. <https://doi.org/10.3390/ijms222312827>
- Godwin, W. C., Hoffmann, G. F., Gray, T. J., & Hughes, R. M. (2019). Imaging of morphological and biochemical hallmarks of apoptosis with optimized optogenetic tools. *Journal of Biological Chemistry*, 294(45), 16918-16929. <https://doi.org/10.1074/jbc.RA119.009141>
- Hafeez, U., Parakh, S., Gan, H. K., & Scott, A. M. (2020). Antibody–drug conjugates for cancer therapy. *Molecules*, 25(20), 4764. <https://doi.org/10.3390/molecules25204764>
- Hidalgo, M., Cascinu, S., Kleeff, J., Labianca, R., Löhr, J. M., Neoptolemos, J., ... & Heinemann, V. (2015). Addressing the challenges of pancreatic cancer: future directions for improving outcomes. *Pancreatology*, 15(1), 8-18. <https://doi.org/10.1016/j.pan.2014.10.001>
- Klussman, K., Mixan, B. J., Cervený, C. G., Meyer, D. L., Senter, P. D., & Wahl, A. F. (2004). Secondary mAb–vcMMAE conjugates are highly sensitive reporters of antibody internalization via the lysosome pathway. *Bioconjugate chemistry*, 15(4), 765-773. <https://doi.org/10.1021/bc049969t>
- Kordes, M., Yu, J., Malgerud, O., Gustafsson Liljefors, M., & Löhr, J. M. (2019). Survival benefits of chemotherapy for patients with advanced pancreatic cancer in a clinical real-world cohort. *Cancers*, 11(9), 1326. <https://doi.org/10.3390/cancers11091326>
- Kurlinkus, B., Ger, M., Kaupinis, A., Jasiunas, E., Valius, M., & Sileikis, A. (2021). CEACAM6's role as a chemoresistance and prognostic biomarker for pancreatic cancer: a comparison of CEACAM6's diagnostic and prognostic capabilities with those of CA19-9 and CEA. *Life*, 11(6), 542. <https://doi.org/10.3390/life11060542>
- Luo, Y. (2022). The role of radiotherapy for pancreatic malignancies: a population-based analysis of the SEER database. *Clinical and Translational Oncology*, 24, 76-83. <https://doi.org/10.1007/s12094-021-02671-0>

- National Cancer Institute. (n.d.). *SEER Cancer Stat Facts: Pancreatic Cancer*. National Institutes of Health. <https://seer.cancer.gov/statfacts/html/pancreas.html>
- Pandey, R., Zhou, M., Islam, S., Chen, B., Barker, N. K., Langlais, P., Srivastava, A., Luo, M., Cooke, L. S., Weterings, E., & Mahadevan, D. (2019). Carcinoembryonic antigen cell adhesion molecule 6 (CEACAM6) in Pancreatic Ductal Adenocarcinoma (PDA): An integrative analysis of a novel therapeutic target. *Scientific reports*, 9(1), 18347. <https://doi.org/10.1038/s41598-019-54545-9>
- Quacquarelli Symonds. (2022). *QS World University Rankings 2023: Top global universities*. <https://www.topuniversities.com/university-rankings/world-university-rankings/2023?&tab=indicators&search=taipei%20medical>
- Rawla, P., Sunkara, T., & Gaduputi, V. (2019). Epidemiology of pancreatic cancer: global trends, etiology and risk factors. *World journal of oncology*, 10(1), 10. <https://doi.org/10.14740%2Fwjon1166>
- Saraste, A., & Pulkki, K. (2000). Morphologic and biochemical hallmarks of apoptosis. *Cardiovascular research*, 45(3), 528-537. [https://doi.org/10.1016/s0008-6363\(99\)00384-3](https://doi.org/10.1016/s0008-6363(99)00384-3)
- Taipei Medical University. (2019). *From Bench to Beside and Back: TMU's International PhD Program for Translational Science*. <https://oge.tmu.edu.tw/phd-of-translational-medicine/>
- Taipei Medical University. (n.d.^a). *Message from the President*. <https://eng.tmu.edu.tw/Front/AboutTMU/Page.aspx?id=QTwn%2B%2BDDe40=>
- Taipei Medical University. (n.d.^b). *About the Program*. <https://pts.tmu.edu.tw/about-the-program/>
- Times Higher Education. (2023). *Asia University Rankings 2023*. https://www.timeshighereducation.com/world-university-rankings/2023/regional-ranking#!/length/-1/sort_by/rank/sort_order/asc/cols/stats
- Wagener, J. (2021). *Cell seeding protocol – Guide on how to seed cells correctly*. Eppendorf Handling Solutions.

<https://handling-solutions.eppendorf.com/cell-handling/about-cells-and-culture/detailview/news/cell-seeding-protocol-guide-on-how-to-seed-cells-correctly/>

Wang, X., Zhang, H., & Chen, X. (2019). Drug resistance and combating drug resistance in cancer.

Cancer Drug Resistance, 2(2), 141. <https://doi.org/10.20517/cdr.2019.10>

Watanabe, M., Sheriff, S., Lewis, K. B., Cho, J., Tinch, S. L., Balasubramaniam, A., & Kennedy, M. A.

(2012). Metabolic profiling comparison of human pancreatic ductal epithelial cells and three pancreatic cancer cell lines using NMR based metabonomics. *Journal of molecular biomarkers & diagnosis*, 3(2). <https://doi.org/10.4172%2F2155-9929.S3-002>

World Cancer Research Fund International. (2022). *Pancreatic cancer statistics*.

<https://www.wcrf.org/cancer-trends/pancreatic-cancer-statistics/#:~:text=Latest%20pancreatic%20cancer%20data,of%20pancreatic%20cancer%20in%202020>